← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › IMMUNE SERA AND IMMUNOGLOBULINS › IMMUNOGLOBULINS › Specific immunoglobulins
varicella/zoster immunoglobulin
J06BB03
Forms & Strengths
- Injectable solution: 125 units / vial (approximate IgV titer per vial)
Adult Dosing
- Postexposure prophylaxis: 125 units per 10 kg up to a maximum of 625 units (5 vials) administered intramuscularly as soon as possible (ideally within 96 hours, up to 10 days) after exposure.
Pediatric Dosing
- Postexposure prophylaxis (<10 kg): 125 units IM as soon as possible after exposure.
- Postexposure prophylaxis (10-19.9 kg): 250 units IM.
- Postexposure prophylaxis (20-29.9 kg): 375 units IM.
- Postexposure prophylaxis (30-39.9 kg): 500 units IM.
- Postexposure prophylaxis (>=40 kg): 625 units IM.
Indications
- Passive immunization for postexposure prophylaxis of varicella in susceptible high-risk individuals (e.g., immunocompromised patients, newborns of mothers with varicella around delivery, premature infants, pregnant women).
Mechanism of Action
- Contains high-titer human antibodies (IgG) against Varicella-Zoster Virus (VZV), which neutralize the virus and modify or prevent varicella infection in susceptible exposed individuals.
Contraindications
- History of severe systemic hypersensitivity or anaphylactic reactions to human immune globulin preparations.
- Individuals with selective IgA deficiency who have antibodies against IgA.
- Do not administer intravenously.
Adverse Reactions
- Local soreness, redness, and swelling at the injection site.
- Mild systemic reactions including fever, headache, malaise, and nausea.
- Rarely: hypersensitivity reactions, anaphylaxis, angioedema.
Drug Interactions
- Live-virus vaccines (e.g., MMR, varicella): Passive antibodies can interfere with the immune response to live vaccines; delay live vaccination for 3 to 5 months following administration of varicella-zoster immune globulin.
Curated Content: Needs Vetting Before Put to Clinical Use